利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.038 秒)

    COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION
    1.
    发明申请
    COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION 审中-公开
    用于调节C依赖性细胞因子生产的组合物和方法

    公开(公告)号：US20080227114A1

    公开(公告)日：2008-09-18

    申请号：US11972592

    申请日：2008-01-10

    申请人： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

    发明人： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

    IPC分类号： G01N33/53 ,  C12Q1/02

    CPC分类号： G01N33/5035 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2333/54 ,  G01N2500/10

    摘要： The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.

    摘要翻译： 本发明涉及用于调节c依赖性依赖性细胞因子产生的组合物和方法，而不会显着改变NFkappaB的表达水平和/或IkappaB的量。 本发明还涉及通过测定c-Rel的改变的亚细胞定位确定的c-Rel活性的调节剂，但其中NFkappaB的表达水平和/或IkappaB的量在实质上未改变。

    Compositions and methods for modulating c-Rel-dependent cytokine production
    2.
    发明申请
    Compositions and methods for modulating c-Rel-dependent cytokine production 审中-公开
    用于调节c-Rel依赖性细胞因子产生的组合物和方法

    公开(公告)号：US20050282232A1

    公开(公告)日：2005-12-22

    申请号：US10986553

    申请日：2004-11-10

    申请人： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

    发明人： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

    IPC分类号： A61K20060101 ,  G01N33/50 ,  G01N33/53 ,  G01N33/567

    CPC分类号： G01N33/5035 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2333/54 ,  G01N2500/10

    摘要： The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.

    摘要翻译： 本发明涉及用于调节c依赖性依赖性细胞因子产生的组合物和方法，而不会显着改变NFkappaB的表达水平和/或IkappaB的量。 本发明还涉及通过测定c-Rel的改变的亚细胞定位确定的c-Rel活性的调节剂，但其中NFkappaB的表达水平和/或IkappaB的量在实质上未改变。

    COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION 审中-公开
    用于调节C依赖性细胞因子生产的组合物和方法

    公开(公告)号：US20120208203A1

    公开(公告)日：2012-08-16

    申请号：US13367825

    申请日：2012-02-07

    申请人： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

    发明人： Rongzhen Lu ,  James Barsoum ,  Yumiko Wada

    IPC分类号： G01N33/53 ,  C12Q1/02

    CPC分类号： G01N33/5035 ,  G01N33/6872 ,  G01N2333/4703 ,  G01N2333/54 ,  G01N2500/10

    摘要： The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.

    摘要翻译： 本发明涉及用于调节c依赖性依赖性细胞因子产生的组合物和方法，而不会实质性地改变NF和κB的表达水平和/或I＆Kgr B的量。 本发明还涉及通过测定c-Rel的改变的亚细胞定位确定的c-Rel活性调节剂的筛选，但其中NF和κB的表达水平和/或I＆Kgr B的量在实质上未改变。

    Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations
    4.
    发明申请
    Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations 审中-公开
    用于产生具有降低复制型腺病毒污染和新型腺病毒载体和制剂的腺病毒载体制备物的新方法

    公开(公告)号：US20080193484A1

    公开(公告)日：2008-08-14

    申请号：US11666221

    申请日：2005-10-25

    申请人： Xinzhong Wang ,  George C. Kaynor ,  James Barsoum

    发明人： Xinzhong Wang ,  George C. Kaynor ,  James Barsoum

    IPC分类号： A61K39/00 ,  C12N15/00 ,  C12N5/00 ,  A61K48/00

    CPC分类号： C12N15/86 ,  A61K48/00 ,  A61K2039/53 ,  C12N2710/10343 ,  C12N2830/42 ,  C12N2840/203

    摘要： This invention provides novel replication-defective adenoviral vectors comprising an adenoviral genome in which the protein IX gene, preferably under the control of its own promoter, is in an inverted orientation relative to the direction of transcription of the native protein IX gene at a location where the protein IX gene normally resides, for production of replication-competent adenovirus (RCA) free, or substantially RCA-free, adenovirus preparations. Said vector preferably encodes a gene of interest. The invention relates to viral particles, host cells and compositions comprising said adenoviral vector. This invention further relates a method for propagating adenovirus preparations, free, or substantially free, of replication-competent adenovirus (RCA) particles, from host cells comprising vectors of this invention, for use to treat a subject suffering from a disease or disorder or to prevent a subject from getting a disease or disorder, such as cancer. The invention also provides methods of treating such subjects and methods of prophylactically treating unaffected subjects. This invention further provides for vaccine compositions comprising the novel replication-defective adenoviral vectors of the present invention.

    摘要翻译： 本发明提供了新的复制缺陷型腺病毒载体，其包含腺病毒基因组，其中优选在其自身启动子控制下的蛋白质IX基因相对于天然蛋白IX基因转录方向处于倒置方向， 蛋白质IX基因通常存在，用于产生无复制的腺病毒（RCA）或基本上不含RCA的腺病毒制剂。 所述载体优选编码感兴趣的基因。 本发明涉及包含所述腺病毒载体的病毒颗粒，宿主细胞和组合物。 本发明还涉及从包含本发明载体的宿主细胞中扩增游离或基本上游离的具有复制能力的腺病毒（RCA）颗粒的腺病毒制剂的方法，用于治疗患有疾病或病症的受试者或 防止受试者患有疾病或病症，如癌症。 本发明还提供了治疗这些受试者的方法和预防性治疗未受影响的受试者的方法。 本发明进一步提供包含本发明的新型复制缺陷型腺病毒载体的疫苗组合物。

    Bis(thio-hydrazide amides) for increasing Hsp70 expression
    6.
    发明授权
    Bis(thio-hydrazide amides) for increasing Hsp70 expression 有权
    用于增加Hsp70表达的双（硫代酰肼酰胺）

    公开(公告)号：US08148426B2

    公开(公告)日：2012-04-03

    申请号：US11281923

    申请日：2005-11-17

    申请人： James Barsoum

    发明人： James Barsoum

    IPC分类号： A61K31/16

    CPC分类号： A61K45/06 ,  A61K31/16 ,  A61K31/165 ,  A61K31/275 ,  A61K31/277 ,  A61K2300/00

    摘要： A method of treating a Hsp70-responsive disorder in a subject includes administering to the subject an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt or solvate thereof. Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C═Z groups to which it is bonded, is an optionally substituted aromatic group.R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group.Z is O or S.

    摘要翻译： 治疗受试者中Hsp70反应性障碍的方法包括向受试者施用有效量的由结构式I表示的化合物或其药学上可接受的盐或溶剂化物。 Y是共价键或任选取代的直链烃基，或Y与它们所键合的两个> C = Z基团一起是任选取代的芳族基团。 R 1 -R 4独立地是-H，任选取代的脂族基团，任选取代的芳基，或者R 1和R 3与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H，任选取代的脂族基团或任选取代的芳基。 Z是O或S.

    Methods of increasing natural killer cell activity for therapy
    10.
    发明申请
    Methods of increasing natural killer cell activity for therapy 审中-公开
    增加治疗自然杀伤细胞活性的方法

    公开(公告)号：US20090042991A1

    公开(公告)日：2009-02-12

    申请号：US11918354

    申请日：2006-04-13

    申请人： James Barsoum ,  Zhenjian Du

    发明人： James Barsoum ,  Zhenjian Du

    IPC分类号： A61K31/15

    CPC分类号： A61K31/165 ,  A61K31/16 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/49 ,  Y02A50/491 ,  Y02A50/492

    摘要： Methods of employing bis(thio-hydrazide amides) to increase NK cell activity in a subject in need thereof, e.g., a subject with an infection or an immunodeficiency, are provided such that the disorder is not cancer, a proliferative cell disorder, a non-infective heat shock protein 70 (Hsp70) responsive disorder, or a proteasome-inhibitor responsive disorder. Typically, a subject, e.g., a human, can be in need of increased NK cell activity has an immunodeficiency or is treated for an infection (e.g., a bacterial, viral, fungal, or parasite infection, or a combination thereof). The method includes administering to the subject an effective amount of a compound represented by Structural Formula I: Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

    摘要翻译： 提供了使用双（硫代酰肼）酰胺来增加有需要的受试者例如具有感染或免疫缺陷的受试者的NK细胞活性的方法，使得该病症不是癌症，增殖性细胞病症， - 感染性热休克蛋白70（Hsp70）反应性病症或蛋白酶体抑制剂反应性病症。 通常，受试者（例如人）可能需要增加的NK细胞活性具有免疫缺陷或被治疗用于感染（例如细菌，病毒，真菌或寄生虫感染或其组合）。 该方法包括向受试者施用有效量的由结构式I表示的化合物：Y是共价键或任选取代的直链烃基，或Y与它们同时存在的两个> C = Z基团一起 是任选取代的芳族基团。 R 1 -R 4独立地是-H，任选取代的脂族基团，任选取代的芳基，或者R 1和R 3与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H，任选取代的脂族基团或任选取代的芳基。 Z是O或S.